Satellos Bioscience Inc. (MSCLF)
OTCMKTS
· Delayed Price · Currency is USD
0.4600
-0.0200 (-4.17%)
May 16, 2025, 2:37 PM EDT
Satellos Bioscience Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
74.71M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| BioStem Technologies | 332.45M |
Satellos Bioscience News
- 4 days ago - Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress - Business Wire
- 10 days ago - Satellos to Present at the CureDuchenne FUTURES National Conference - Business Wire
- 18 days ago - Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference - Business Wire
- 6 weeks ago - Satellos to Participate in Two April Investor Conferences - Business Wire
- 7 weeks ago - Satellos Reports 2024 Financial Results and Highlights Company Progress - Business Wire
- 2 months ago - Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 3 months ago - Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 3 months ago - Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers - Business Wire